Cardoz: Anti-inflammatory synergy

Over the past decade, it's become clear that atherosclerosis is a chronic inflammatory disease to which inflammatory cells, in particular mast cells, are major contributors. Based on this shift in the understanding of disease pathology, Cardoz AB believes its combination products targeting the inflammatory components of atherosclerosis and lipoproteins may provide benefit over current treatments.

Cardoz's lead product combines an undisclosed statin with CDZ-001, an off-patent oral mast cell inhibitor that is marketed in Asia but not approved in the U.S. or Europe. The company also is researching NCEs against leukotriene A4 hydrolase (LTA4H), a new cardiovascular target involved in inflammation...